Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456856 · ClinicalTrials.gov registry record · Phase 4
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
A Phase 4 study of Heart Failure (HF), sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT03456856 is a Phase 4 study of Heart Failure (HF) that has completed, run by Amgen. The registered enrollment target is 30 participants, below the 168-participant average among 3 other Heart Failure (HF) trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03456856, a Phase 4 study of Heart Failure (HF), has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF). There will be a 7-day screening period, a 57-day open-label treatment period, and a safety follow-up at day 87 or 30 days after the last administration of the investigational product.
Conditions Studied
Interventions
- DRUG Ivabradine
Study Locations (3)
Delaware
- Research Site - Wilmington
Michigan
- Research Site - Detroit
New York
- Research Site - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2019-05-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03456856
The ClinicalTrials.gov registry entry for NCT03456856 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 3 other Heart Failure (HF) trials with a reported enrollment target (82% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure (HF) appearing as the primary indexed condition, and to 1 intervention - of which Ivabradine is the first listed.
NCT03456856 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Delaware, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT03456856 about?
NCT03456856 is a clinical study titled "A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.". This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF). There will be a 7-day screening period, a 57-day open-label treatment period, and a safety follow-up at day 87 or 30 days after the las...
What is the current status of trial NCT03456856?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2017-09-28. Estimated completion is 2019-05-20.
What conditions does trial NCT03456856 study?
This clinical trial studies the following conditions: Heart Failure (HF).
What interventions are being tested in trial NCT03456856?
The interventions under investigation include: Ivabradine (DRUG).
Who is sponsoring clinical trial NCT03456856?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03456856 being conducted?
This trial has 3 study locations across Delaware, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure (HF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
COMPLETED · Phase 4
-
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
RECRUITING · NA
-
REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.